Loading...
Loading...
Browse all stories on DeepNewz
VisitTotal HI-Bio milestone payments by Biogen by end of 2025
Less than $200 million • 25%
$200 million to $400 million • 25%
$400 million to $600 million • 25%
More than $600 million • 25%
Biogen financial disclosures or SEC filings
Biogen (Nasdaq: $BIIB) to Acquire HI-Bio for $1.15 Billion Upfront and $650 Million in Milestones
May 22, 2024, 11:39 AM
Biogen Inc. (Nasdaq: $BIIB) announced on Wednesday that it has agreed to acquire privately held Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in potential milestone payments. The acquisition aims to bolster Biogen's late-stage pipeline and expand its immunology portfolio. HI-Bio is a clinical-stage biotechnology company focused on targeted therapies, including Felzartamab, a Phase 3 CD38 antibody for immunosuppression and other immune-related diseases.
View original story
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Under $200 million • 25%
Between $200 million and $500 million • 25%
Between $500 million and $800 million • 25%
Over $800 million • 25%
Below $100 million • 33%
Between $100 million and $300 million • 34%
Above $300 million • 33%
Yes • 50%
No • 50%
Increase by more than 5% • 25%
Increase by less than 5% • 25%
Decrease by less than 5% • 25%
Decrease by more than 5% • 25%
Less than $200M • 25%
$200M to $400M • 25%
$400M to $600M • 25%
More than $600M • 25%
Full $1.7 billion paid • 33%
Partial milestone payments made • 33%
No milestone payments made • 34%
No milestones achieved • 33%
Only first milestone achieved • 33%
All milestones achieved • 33%
Revenue from Imdelltra exceeds $1 billion • 25%
Revenue from Imdelltra is $500 million to $1 billion • 25%
Revenue from Imdelltra is $100 million to $500 million • 25%
Revenue from Imdelltra is less than $100 million • 25%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $2 billion • 25%
More than $2 billion • 25%
Increase 5% to 10% • 25%
Decrease more than 5% • 25%
Decrease or change less than 5% • 25%
Increase more than 10% • 25%